Drug Updates
Updates relating to drug and treatment approvals by the FDA, important recalls, and urgent drug-related news. Please check back often.
New AD Cream for Adult Children 2 years and Older (tapinarof)
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
What is D.R.E.S.S? (Drug Reaction with Eosinophilia and Systemic Symptoms)
Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver injury. Many drugs could cause D.R.E.S.S., but the most common drugs involved are specific types of antibiotics…
Non-steriodal cream treatment option approved by FDA for Atopic Dermatitis (Roflumilast cream)
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
FDA Greenlights Pemgarda for High-Risk COVID-19 Prevention
This is particularly important for the immunocompromised population, who are at greater risk of severe illness and have a diminished response to vaccines.
FDA approved chronic sinusitis medication without nasal polyps
US FDA approved of XHANCE as the first and only medication for adults with chronic rhinosinusitis without nasal polyps. It is a fluticasone propionate nasal spray which uses the Exhalation Delivery System to enable topical steroid to the inflamed areas and is proven effective.